Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States.
J Med Chem. 2017 Dec 28;60(24):10056-10070. doi: 10.1021/acs.jmedchem.7b01293. Epub 2017 Dec 8.
USP7 is a deubiquitinase implicated in destabilizing the tumor suppressor p53, and for this reason it has gained increasing attention as a potential oncology target for small molecule inhibitors. Herein we describe the biophysical, biochemical, and computational approaches that led to the identification of 4-(2-aminopyridin-3-yl)phenol compounds described by Kategaya ( Nature 2017 , 550 , 534 - 538 ) as specific inhibitors of USP7. Fragment based lead discovery (FBLD) by NMR combined with virtual screening and re-mining of biochemical high-throughput screening (HTS) hits led to the discovery of a series of ligands that bind in the "palm" region of the catalytic domain of USP7 and inhibit its catalytic activity. These ligands were then optimized by structure-based design to yield cell-active molecules with reasonable physical properties. This discovery process not only involved multiple techniques working in concert but also illustrated a unique way in which hits from orthogonal screening approaches complemented each other for lead identification.
USP7 是一种去泛素化酶,涉及不稳定肿瘤抑制因子 p53,因此它作为小分子抑制剂的潜在肿瘤靶点引起了越来越多的关注。本文描述了导致 Kategaya 发现的 4-(2-氨基吡啶-3-基)苯酚化合物( Nature 2017 ,550 ,534-538 )被鉴定为 USP7 特异性抑制剂的生物物理、生物化学和计算方法。NMR 结合虚拟筛选和重新挖掘生化高通量筛选 (HTS) 命中的片段发现先导化合物 (FBLD) 导致了一系列结合 USP7 催化结构域“手掌”区域并抑制其催化活性的配体的发现。然后,通过基于结构的设计对这些配体进行优化,得到具有合理物理性质的细胞活性分子。这一发现过程不仅涉及多种技术的协同作用,还说明了正交筛选方法的命中相互补充以确定先导化合物的独特方式。